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860 The Journal of Thoracic and CardioObjectives: A large number of experimental studies have indicated that blood
cardioplegia might be superior to crystalloid cardioplegia for myocardial
protection during ischemic arrest. However, no prospectively randomized
studies of large patient series have been undertaken to prove potential differ-
ences in clinical course.
Methods: Over a 52-month period, all patients undergoing on-pump coronary
artery bypass operated on by 2 surgeons were prospectively randomized to
receive either cold crystalloid cardioplegia (group C) or cold blood cardio-
plegia (group B) during aortic crossclamping.
Results: Altogether, 1440 patients aged 37 to 89 years (median, 66 years)
entered the study (group C, n  719; group B, n  721). The groups were
comparable in all major demographic, preoperative, and operative variables.
The clinical course turned out to be nearly identical for both groups. No statistically
significant differences were seen concerning spontaneous sinus rhythm after aortic
declamping, use of inotropic drugs or intra-aortic balloon pumping, postoperative
ventilatory support, bleeding and rate of allogeneic blood transfusions, perioperative
myocardial infarction, episodes of atrial fibrillation, stroke or minor neurologic
dysfunction, renal function, infections, physical rehabilitation, or mortality. Also, in
subgroups of patients at higher operative risk (female sex, age 70 years, unstable
angina, diabetes, emergency operation, ejection fraction 0.50, crossclamping time
50 minutes, and EuroSCORE4), no statistically significant differences could be
demonstrated between the groups.
Conclusions: There were no significant differences whether myocardial protection
was performed with cold blood cardioplegia or cold crystalloid cardioplegia during
aortic crossclamping in patients undergoing coronary artery bypass grafting. The
extra costs related to blood cardioplegia might be saved.
The optimal method for protection of the myocardium during isch-emic arrest has been debated since the very beginning of moderncardiac surgery. A large variety of techniques have been advocated,and obviously few institutions have identical protocols for myocar-dial protection. This makes true differences in clinical results verydifficult to evaluate. However, 2 main techniques have gained wide-
spread acceptance: cardiac arrest induced and maintained with potassium added to
a blood-based solution or a crystalloid-based solution. Several experimental studies
favor the use of blood cardioplegia when investigating release of cardiac enzymes,
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Pmetabolic response, and other laboratory test results.1 In
clinical studies focusing on patient outcome variables, the
effects of blood cardioplegia have most often been matched
with those in historical control groups, with indications of
being superior to the effects of crystalloid cardioplegia.2,3
However, no larger prospectively randomized studies have
thus far been reported.
The present investigation was designed and performed in
a standardized fashion to minimize the inevitable problems
of methodologic bias when performing clinical studies. The
patient material included only patients undergoing coronary
artery bypass grafting (CABG) with no additional opera-
tions who were operated on by 2 senior surgeons. The
practices of surgical techniques, such as aortic crossclamp-
ing, use of the internal thoracic artery, body temperature,
and mode of administration of cardioplegia, were identical
throughout the study period. The postoperative management
was standardized in all aspects, including a nonpharmaco-
logic blood conservation strategy and a fast-tracking recov-
ery protocol. The same staff of anesthetists and perfusionists
treated all patients during the entire study. Thus the method
of prospective randomization of all patients left the only
difference between the 2 groups to be the composition of the
cardioplegic solution.
The major aim of the study was to investigate all relevant
clinical outcome variables in a large and homogenous pa-
tient population. Except for routine monitoring of enzymes
indicating perioperative myocardial infarction, no other bio-
chemical markers to evaluate myocardial function were
studied.
Material and Methods
Patients
From January 2000 through April 2003, 1440 consecutive patients
undergoing on-pump CABG operated on by one of 2 surgeons
(EØ, GT) entered the study. Four patients operated on without
aortic crossclamping and one patient having CABG without car-
diopulmonary bypass (CPB) were excluded. No other patients
TABLE 1. Demographic variables and operative risk facto
blood cardioplegia (group B)
Variables G
Age (y)
Age 70 y (% of patients)
Female sex (%)
Weight (kg)
Diabetes (% of patients)
Emergency operation (% of patients)
Redo operation (% of patients)
Ejection fraction
Ejection fraction 0.5 (% of patients)
Previous myocardial infarction (% of patients)
EuroSCORE 4-12; mean, 5.6 (% of patients)undergoing coronary bypass were excluded for any reasons during
The Journal of Thoracithe period under investigation. Informed consent was not obtained
from the patients because both methods of myocardial protection
are universally accepted.
The majority of the patients underwent surgical intervention on
an elective basis. About 20% were emergency cases, identified as
patients operated on within 1 week after onset of symptoms, after
angiography, or both. Thirty-five (2.4%) patients had their second
revascularization, with equal distribution across the groups (Table
1). Diabetic patients were defined as those using insulin (6.9%) or
receiving oral medication (8.5%). The patient material is some-
what selected because of the close collaboration with a neighbor-
ing university department, in which care is provided to patients
with severe renal dysfunction, patients with ventricular aneurysms,
and patients in need of combined carotid and coronary operations
and acute operations after failed angioplasties. Table 1 outlines the
patient characteristics of both groups.
Anesthesia and Operation
The anesthesia protocol was designed to permit early postoperative
extubation. After induction with diazepam (0.1-0.2 mg/kg), fent-
anyl (3- 5 g/kg), thiopenthal (0.5-2.0 mg/kg), and pancuronium
bromide (0.1 mg/kg), anesthesia was maintained with isoflurane
(0.5% to 1.0% inspired). During CPB, propofol (2-4 mg · kg1 ·
h1) was given in addition to fentanyl (1-2 g/kg).
The extracorporeal circulation was performed with a Sto¨ckert
roller pump with a pulsatile flow control (PFC III; Sto¨ckert Instru-
mente GmbH, Munich, Germany). Because of the routine practice
of our institution, all CPB was undertaken with heparin-coated
systems. The Carmeda Bio-Active Surface system (Medtronic Inc,
Minneapolis, Minn) and the Duraflo II equipment (Baxter Health-
care Corp, Bentley Laboratories Division, Irvine, Calif) were used
in equal numbers in both groups. The circuits were primed with
2000 mL of Ringer acetate. Systemic heparinization was reduced
(activated clotting time [ACT] 250 seconds) in all first-time
operations, and a full heparin dose (ACT 480 seconds) was
administered in all redo cases. The standard sizes of the aortic and
the 2-stage venous cannulas were 22F and 48F, respectively. Mild
hypothermia (blood temperature 32°C) was instituted immediately
after the start of bypass. A cardiotomy suction line was available
patients receiving crystalloid cardioplegia (group C) and
C (n  719) Group B (n  721) P value
.0 9.2 64.9 9.8 .95
35.0 35.8 .81
20.0 20.4 .86
.2 14.2 81.5 14.1 .33
13.9 16.8 .34
19.3 19.1 .94
2.4 2.5 .70
8 0.14 0.68 0.14 .76
13.4 13.9 .88
51.0 50.5 .85
41.0 44.2 .24rs in
roup
65
82
0.6and frequently used during CPB.
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CSPThe aorta was crossclamped during performance of the distal
anastomoses. At least one internal thoracic artery anastomosis was
constructed in almost all patients (Table 2), and this was supple-
mented with saphenous vein grafts or the radial artery in some
cases. The proximal anastomoses were performed during partial
occlusion of the ascending aorta while the patient was being
rewarmed.
Myocardial Protection
Group B. A Duraflo II coated (D II HE-30 Gold; (Baxter
Healthcare Corp, Bentley Laboratories Division) blood cardiople-
gia set was used in all patients. The cardioplegia set was mounted
on a double-pump system with a slave function combined with a
heater-cooler unit. At reduced ACT (250 seconds), the cardio-
plegia system was circulated at all times until the end of CPB.
The blood cardioplegia was mixed at a ratio of 1:4 and
delivered antegradely into the aorta. A volume of 500 to 800
mL was given initially until cardiac arrest, and thereafter, 100
to 300 mL was given if return of electrical activity was seen.
The temperature ranged between 6°C and 10°C. The concen-
trations of the components were as follows: potassium chloride,
20 mmol/L; magnesium chloride, 17 mmol/L; calcium chloride,
2 mmol/L; procaine hydrochloride, 1 mmol/L; bicarbonate, 25
mmol/L; and Ph, 7.35 to 7.45. Compared with crystalloid car-
dioplegia, the lines for blood cardioplegia represented an extra
cost of about $130 US.
Group C. The cardioplegic solution was mixed in Ringer ac-
etate and stored at 4°C. The temperature of the infusate was about
4°C to 8°C. The mode of administration and concentration of
electrolytes and procaine was identical in the 2 groups.
The blood conservation protocol of the institution, previously
described in detail,4 was applied to all patients. Normovolemic
anemia was accepted to a hematocrit level of 0.25 postoperatively;
a level less than this was considered an indication for allogeneic
red blood cell transfusion. The hemoglobin concentration and
platelet count were determined preoperatively, at 3 hours and 18
TABLE 2. Operative variables in patients receiving crys-
talloid cardioplegia (group C) and blood cardioplegia
(group B)
Variables
Group C
(n  719)
Group B
(n  721) P value
Amount of cardioplegic
solution given (mL)
810 173 817 287 .08
At least one internal thoracic
artery anastomosis (% of
patients)
99.9 99.4 .86
No. of distal anastomoses 4.5 1.2 4.6 1.1 .02
Ischemic time (min) 33.5 10.0 34.1 9.1 .18
Extracorporeal time (min) 52.2 11.6 53.5 11.6 .04
Spontaneous sinus rhythm
after declamping (% of
patients)
85.3 81.8 .13hours postoperatively, and at discharge on the fifth to seventh day.
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After routine electrocardiogram (ECG) registration during the day
of the operation, all patients were monitored with continuous
telemetry for 48 hours. In cases of arrhythmias, telemetry was
prolonged or reinstituted. All patients having one or more episodes
of arrhythmias were prospectively registered. Preoperative medi-
cation (-blockers, Ca-channel blockers, and digitalis) were
continued from the first day after the operation. In those patients
not receiving -blockers preoperatively, such treatment was insti-
tuted at the first postoperative day.
Diagnosis of Perioperative Myocardial Infarction
All patients had serial 12-lead ECG examination and enzyme
analysis preoperatively and at 6, 24, and 48 hours postoperatively,
as well as at discharge from the hospital. The interpretations of the
ECGs were prospectively done by experienced consultant cardiol-
ogists who made their diagnosis blindly related to the study.
Development of new Q-waves of more than 0.03 seconds, in
combination with a significant increase of aspartate aminotrans-
ferase and creatine kinase MB exceeding 2.5 as the upper normal
level, was defined as definite myocardial necrosis.
Rehabilitation
After the operation, the patients were extubated as soon as possible
after cardiorespiratory stabilization. For practical reasons, the pa-
tients stayed in the intensive care unit until the next morning. Most
often, the mediastinal drains and the venous and arterial lines were
then removed, and the patients were taken out of bed for light
physical training. From the third postoperative day, the patients
were usually allowed to move freely outside the hospital. A de-
tailed registration of the steps of physical recovery was included in
the patient data form.
Statistical Analysis
Comparison of the 2 groups was done by using the Mann-Whitney
U test for continuous variables. Discrete variables were treated by
means of contingency tables, with the Yates correction and the
Fisher test performed when one of the expected cell values was
less than 5. The data are presented as means  SDs. All data were
recorded prospectively and stored in a database.
Results
The demographic data are listed in Table 1, and there were
no statistically significant differences between the groups.
There were slightly statistically significant differences in the
number of distal anastomoses and the time for extracorpo-
real circulation (Table 2). However, from a clinical point of
view, the disparities were negligible. The total amount of
cardioplegic solution was similar in both groups. Although
group C received about 600 mL more clear fluid in the
cardioplegic solution, the fluid balance at arrival in the
intensive care unit was not accordingly different (Table 2),
indicating that the anesthetist, perfusionist, or both, because
of common indications, added more fluid to group B during
the operation. Sinus rhythm returned spontaneously after
declamping of the aorta at equal proportion in the 2 groups.
mber 2004
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PThe postoperative mediastinal drainage was somewhat
reduced in group B (Table 3). Although the difference was
statistically significant, the clinical effect was hardly notice-
able. The need for transfusion of allogeneic blood products
was low in both groups, without intergroup differences.
The additional clinical outcome variables are shown in
Table 4. The patients were extubated early in both groups.
There were no differences in the rate of perioperative myo-
cardial infarction, use of inotropic drugs, arrhythmias, inci-
dence of neurologic complications, infections, or progress
of physical rehabilitation. Thirty-day mortality was 0.4% (3
patients) in group C and 0.6% (4 patients) in group F (P 
.071).
The following subgroups of higher-risk patients were
tested for all preoperative and postoperative variables,
which are included in Tables 2 to 4: age greater than 70
years (n  445); unstable angina–urgent operation (n 
231); diabetes (n  193); ejection fraction less than 0.5 (n
 166); female sex (n 149); redo operation (n  35);
EuroSCORE greater than 4 (mean, 5.6; n 614); and aortic
crossclamp time of greater than 50 minutes (mean, 56.1
minutes; n  91).
The number of patients was similar across the groups.
There were no statistically significant differences between
the patients in group C or the patients in group B.
In particular, the analysis of patients at higher operative
risk (EuroSCORE, 4-12) did not show any intergroup dif-
ferences (Table 5).
Discussion
There is a magnitude of technical modifications for protect-
ing the heart during ischemic arrest, such as different tem-
perature (cold, tepid, warm),5,6 different administration (an-
tegrade, retrograde, and combinations of both),7,8 additive
substrates, or drugs.3,9-12 The large amount of laboratory
studies, most of them indicating the benefit of blood car-
dioplegia,1,3 do not really help the clinician to evaluate the
effects on the most relevant patient outcome variables,
particularly because of the lack of larger prospectively
TABLE 3. Postoperative variables in patients receiving cry
B)
Variables
Mediastinal drainage 18 h postoperatively (mL)
Resternotomy for bleeding (% of patients)
Red cells (plasma) transfusions (% of patients)
Hemoglobin concentration preoperatively (g/L)
Hemoglobin concentration at discharge (g/L)
Mediastinitis (% of patients)
Moving outside bed on postoperative day 1 (% of patients)
Walking stairs—outdoors before postoperative day 3 (% of patienrandomized patient studies.
The Journal of ThoraciThe definite aim of the present study was to include a
substantial number of patients to obtain sufficient statistical
power for evaluation of the most relevant factors affecting
the postoperative course. The patient selection and manage-
ment was performed in a standardized fashion to overcome
the methodologic problems related to all clinical trials (eg,
various staff, different surgical approaches, variations of
anesthesia protocols over time, and mix of patients). This
was possible because our department is run mainly by only
2 surgeons, and a single anesthetist supervises the intraop-
erative and postoperative treatment of most patients. There-
fore the practices of surgical methods and techniques for
anesthesia and perfusion remained similar throughout the
study period.
Being enthusiastic toward blood cardioplegia for many
years, we were somewhat disappointed after realizing that
no overall clinical benefits were seen when comparing
blood cardioplegia and crystalloid cardioplegia. Even more,
no beneficial effects could be shown in groups of patients at
higher operative risk, such as those with unstable angina,
redo operations, lower ejection fraction, female sex, diabe-
tes, or older age. In fact, a substantial number of patients
with a higher preoperative risk score were available for
analysis, but no statistically significant differences were
demonstrated (Table 5). A general limitation of the study
might be the relatively short mean ischemic time and CPB
time. However, analysis of the subgroup of patients having
a prolonged aortic crossclamping time did not reveal any
significant differences.
Our results are similar to those of other randomized
series,13-15 in which no difference between cold blood and
cold crystalloid cardioplegia could be seen, whereas others
suggested improved myocardial protection with blood car-
dioplegia.1,16,17 The results remain inconclusive and con-
fusing because of the limited number of patients in all the
reported studies. No randomized controlled clinical studies
exceeding 140 adult patients could be traced in the litera-
ture.
Conduction disturbances have been reported with the use
loid cardioplegia (group C) and blood cardioplegia (group
Group C
(n  719)
Group B
(n  721) P value
665 296 631 258 .008
2.4 1.7 .34
5.0 6.9 .13
141 13 141 13 .99
118 14 118 13 .94
0.4 0.4 .68
98.9 99.2 .77
62.0 59.6 .43stalof blood cardioplegia.18 Others19 have demonstrated a
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after blood cardioplegia compared with that after crystalloid
cardioplegia. In the present study no statistical differences
concerning conduction disturbances were seen. The rela-
tively high rate of spontaneous return of sinus rhythm in
both groups might be related to the addition of procaine to
the cardioplegic solution.20
According to the routine practice of our institution, he-
parin-coated extracorporeal circuits were used in every pa-
tient. We and others21,22 have previously demonstrated the
beneficial effects of heparin-coated circuits on the total
body inflammatory response, the incidence of postoperative
atrial fibrillation, and reduced postoperative bleeding.23
These clinical environments might have influenced the
overall clinical results, particularly considering the low
morbidity rate and the 30-day mortality rate. However, for
the present investigation, the technical modification of the
extracorporeal circulation did not interfere with the results
of the study as such because the techniques of CPB were
identical in both groups.
In summary, in this prospectively randomized study in-
cluding a substantial number of patients undergoing CABG,
there were no significant differences in any major clinical
TABLE 4. Cardiopulmonary variables in patients receiving c
B)
Variables
Ventilatory support postoperatively (h)
Perioperative myocardial infarction (% of patients)
Inotropic medication, 30 minutes (% of patients)
Intra-aortic balloon pumping (% of patients)
Postoperative AF; preoperative AF excluded (% of patients)
Stroke (% of patients)
Minor neurologic events (% of patients)
Hospital mortality, 30 d (% of patients)
AF, Atrial fibrillation.
TABLE 5. Postoperative outcome variables in patients at
cardioplegia (group C) and blood cardioplegia (group B)
Variables
EuroSCORE
Ventilatory support postoperatively (h)
Perioperative myocardial infarction (% of patients)
Inotropic medication, 30 min (% of patients)
Intra-aortic balloon pumping (% of patients)
Postoperative AF; preoperative AF excluded (% of patients)
Stroke (% of patients)
Minor neurologic events (% of patients)
Hospital mortality, 30 d (% of patients)
AF, Atrial fibrillation.end points whether the myocardium was protected with cold
864 The Journal of Thoracic and Cardiovascular Surgery ● Deceblood cardioplegia or cold crystalloid cardioplegia during
aortic crossclamping. The extra costs related to mechanical
pumps and disposable equipment might be saved.
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